Ademetionine 1,4-butanedisulfonate, abbreviated SAM-e 1,4-BDS, is the 1,4-butanedisulfonic acid salt of S-adenosyl-L-methionine and is supplied as a pharmaceutical-grade active pharmaceutical ingredient for oral solid dosage forms and injectable preparations. The product is specified for film-coated tablets, hard-gelatin capsules, granule-filled sachets, effervescent granules, and lyophilized or solution injectable presentations. Commercial API designations typically include a particle-size suffix for direct-compression, dry-granulation, or wet-granulation routes; the injectable grade is normally controlled for bioburden and endotoxin before terminal filtration. Unlike the tosylate disulfate salt, the 1,4-butanedisulfonate species contains a divalent sulfonate counterion that alters pH-solubility behaviour, hygroscopicity, and compatibility with common excipients such as microcrystalline cellulose, mannitol, and sodium starch glycolate. The API is handled under current good manufacturing practice as described in 21 CFR 210/211 and ICH Q7, and is released against a specification that includes assay, related substances, water content, residual solvents, elemental impurities, particle size distribution, and microbial limits. Storage is normally at 2–8 °C in low-oxygen, low-humidity barrier packaging.

Specification Boundaries for Solid Oral and Parenteral Dosage Forms

Release specifications for SAM-e 1,4-BDS are established in accordance with ICH Q6A, ICH Q3C, and ICH Q3D, with pharmacopoeial methods selected according to the target market. Assay of the active moiety is determined by ion-pair reversed-phase high-performance liquid chromatography using a method verified for specificity against methylthioadenosine, S-adenosylhomocysteine, and adenine. Related substances are controlled by area normalization; the degradation profile is monitored under forced degradation to confirm mass balance. Water content is determined by Karl Fischer titration according to Ph. Eur. 2.5.12 or USP <731>. Residual solvents are controlled under ICH Q3C class 2 and class 3 limits; ethanol, methanol, and isopropanol are common monitoring targets because of purification pathways. Elemental impurities are aligned with ICH Q3D and USP <232>/<233>, with limits based on the permitted daily exposure for the intended maximum daily dose. Particle size distribution is measured by laser diffraction according to ISO 13320-1:2020; the direct-compression grade is commonly controlled with D90 not exceeding 250 µm, while the injectable grade may be controlled with D90 below 20 µm for rapid dissolution in water for injection. Bulk density, tapped density, and specific surface area are supplied as informational parameters for solid oral process design.

In tablet and capsule manufacturing, the dominant process constraint is moisture ingress during wet massing, aqueous film coating, or capsule shell transfer. Direct compression without pre-granulation is used for low-dose tablets when the API is co-milled with silicified microcrystalline cellulose and pregelatinized starch; the blend is characterized by bulk density 0.35–0.55 g/cm³, Carr index 20–30, and flow function coefficient measured by Schulze ring shear cell. For capsule filling, powder bed relative humidity is held below 40% RH at 18–22 °C to reduce hygroscopic bridging. A dosator or tamping-pin capsule machine may require addition of 0.5–1.0% colloidal silicon dioxide and 0.5–1.5% magnesium stearate; the actual concentrations are established by ejection force and dissolution testing. If wet granulation is unavoidable, a low-shear wet granulation is conducted below 25 °C with binder solution pH 4.5–5.5. The granulate is dried in a fluid-bed dryer with inlet air temperature not exceeding 35 °C and product temperature monitored at 20–25 °C; drying is stopped when water activity is below 0.4 or loss on drying is below 2.0%. Tablet dissolution acceptance is typically evaluated in 0.1 N hydrochloric acid with USP Apparatus II at 50 rpm; a Q value of 80% release in 30 min is commonly used for immediate-release formulations, but the final specification is product-specific.

Why Does the 1,4-Butanedisulfonate Salt Form Shift Stability and Compaction Behaviour Relative to Other Sulfonate Salts?

The 1,4-butanedisulfonate salt differs from the more common p-toluenesulfonate, or tosylate, and disulfate forms in counterion structure, molar mass, and the number of ionizable sulfonate groups. The butanedisulfonate anion is a divalent aliphatic sulfonate with terminal negative charges separated by a four-carbon chain; this arrangement produces a different crystal lattice energy and hydration behaviour than the aromatic tosylate salt. In aqueous solution, the pH of a 10 mg/mL solution may lie between 2.5 and 4.0 for the butanedisulfonate salt, whereas tosylate-based material can differ by 0.5–1.0 pH units under identical conditions. The lower mass fraction of the butanedisulfonate counterion can increase the weight-based assay of the active moiety relative to high-molecular-mass salts; this is a formulation consideration when calculating dose uniformity and tablet mass. Hygroscopicity is influenced by crystallinity and residual water, and reduced deliquescence is observed only when the API is protected from humidity. Published comparative moisture sorption data at 25 °C/60% RH are limited for all SAM-e salts, so each lot should be characterized by dynamic vapour sorption rather than inferred from salt identity alone. The butanedisulfonate form is selected for injectable lyophilized products when the formulation requires high aqueous solubility and absence of an aromatic tosylate chromophore, which can introduce additional related-substance peaks in HPLC. In tablet formulations, the divalent sulfonate can interact with cationic or amine-bearing excipients; dry blends should avoid primary amine additives because the sulfonium centre is susceptible to nucleophilic attack, and such interactions can alter dissolution and degradation profiles.

Granule and sachet formulations present a different process sequence because the API is exposed to high water activity during agglomeration and to acid-base contact in effervescent systems. The powder mixture typically contains mannitol, citric acid, sodium bicarbonate, and a binding polymer. When effervescent components are used, water is held as crystal water and the API is not pre-dissolved in the effervescent couple. Agglomeration is therefore conducted with a non-aqueous or low-water granulation fluid, or with a hydroalcoholic binder at product temperature 20–25 °C. Drying in a fluid-bed dryer is stopped at a water activity below 0.4 or loss on drying below 2.0%. The granule size distribution is controlled by sieve analysis according to USP <786> or ISO 3310-1:2016; the fraction retained on 1000 µm should be low because oversize granules can extend disintegration time. Packaging with silica gel desiccant or molecular sieve is required, and the primary container is an aluminum foil laminate sachet with low moisture vapour transmission rate.

Thermal Degradation Pathways in SAM-e Salt Systems Follow pH-Dependent Intramolecular Cyclization

The sulfonium centre in S-adenosyl-L-methionine is chiral, and the biologically active configuration is the S,S diastereomer. Chiral purity is controlled by a stability-indicating HPLC method capable of separating S,S and R,S forms. Epimerization accelerates with temperature and neutral-to-alkaline pH; formulation pH below 5.5 and processing below 25 °C are standard control points. Degradation products include S-adenosylhomocysteine, methylthioadenosine, and adenine; forced degradation studies are used to set specific and total impurity limits. The 1,4-butanedisulfonate counterion does not eliminate this degradation but influences the pH and water activity of the matrix, which are the two principal stabilising variables. Because the degradation rate is highly sensitive to available water, pre-drying of excipients or use of internal desiccant is required at ambient relative humidity above 60%. Process hold times for aqueous binding solutions should be justified by in-process degradation data rather than by visual appearance alone.

When Lyophilization of Injectable Ademetionine Requires Low-Temperature Annealing and Residual Moisture Control

Injectable SAM-e 1,4-BDS is processed as a lyophilized cake because the sulfonium salt undergoes hydrolysis and intramolecular degradation in aqueous solution at room temperature. The compounding solution is prepared at 2–8 °C in water for injection purged with nitrogen; the target concentration may range from 50 to 100 mg/mL of ademetionine base equivalents in 2 mL or 5 mL vials. The solution pH is adjusted with dilute hydrochloric acid or sodium hydroxide to 4.0–5.5 and held for no more than 8 h before filling to limit S-adenosylhomocysteine formation. Lyophilization cycles require low shelf temperatures, typically −40 to −35 °C for freezing and −20 to −10 °C for primary drying, with chamber pressure 50–150 µbar. The lyophilized cake is required to have residual moisture below 1.5% and reconstitution time below 60 s with 20 °C water for injection. Subvisible particulate matter is controlled according to USP <788> or Ph. Eur. 2.9.19; the parenteral product is sterilized by aseptic filtration through a 0.22 µm membrane rather than terminal steam sterilization because of thermal degradation. On a semi-automatic vial filling line, foaming during filling can be reduced by lowering filling speed and using nitrogen blanketing; the container headspace is flushed with nitrogen before stoppering. Endotoxin control begins with API release testing and continues through depyrogenation of vials and stoppers.

Pharmacopoeial Alignment Is Required Across All Dosage-Form Routes

Final dosage forms must meet the pharmacopoeial test chapters relevant to the route and presentation. Tablet and capsule uniformity is evaluated according to USP <905> or Ph. Eur. 2.9.40. Disintegration testing follows USP <701> or Ph. Eur. 2.9.1; dissolution testing uses USP <711> or Ph. Eur. 2.9.3. Injectable particulate matter is assessed by the light obscuration particle count test of USP <788> or Ph. Eur. 2.9.19. For granule-filled sachets, particle size and mass variation are controlled according to the applicable compendial methods. The table below summarizes the primary release tests that differ by dosage form.

The API should be dispensed in a controlled environment with relative humidity below 40% and temperature 15–25 °C; open-container hold time should be limited to 4 h unless in-process stability data support a longer hold. The material is incompatible with strong oxidizing agents, high-pH disintegrants, and primary amine excipients during wet processing. Polyethylene or polypropylene contact materials are accepted; contact with uncoated metal surfaces should be avoided during prolonged wet massing because sulfonate salts can promote corrosion. Batch-to-batch variability in particle size and water content may influence direct-compression weight uniformity, so incoming lots are qualified by shear-cell flow testing and loss on drying. Stability mapping under ICH Q1A(R2) conditions is required before commercial scale-up because published data for ademetionine 1,4-butanedisulfonate under all humidity and temperature combinations are limited.